Brazil’s healthcare AI market is experiencing a significant boom, with a market value projected to reach USD 21.47 billion by 2031, growing at a robust 20.8% CAGR. This rapid expansion is driven by both private and public sector adoption, with key applications already reshaping clinical practice. AI is being used to accelerate diagnostics, improve hospital operations, and advance genomics, with some services now available at a more affordable cost. This growth is supported by Brazil’s national AI plan (PBIA), which aims to modernize the public health system (SUS) through the use of these advanced technologies.
The proliferation of AI in healthcare is not without its legal framework. Brazil’s Senate has approved Bill No. 2,338/2023, which proposes a risk-based approach to AI regulation. This framework would ban excessively risky AI systems and require high-risk systems, such as diagnostic tools, to undergo rigorous testing, impact assessments, and governance protocols. This is in addition to existing laws like the LGPD (Brazil’s data privacy law) and ANVISA’s regulations for Software as a Medical Device (SaMD), which mandate strict privacy and safety controls. For healthcare professionals, this means a greater focus on data quality, model transparency, and comprehensive documentation to ensure compliance and mitigate risks.
Real-world applications are already widespread. Hospitals and startups are deploying AI for radiology triage, predictive analytics for bed management, and precision medicine. The PBIA’s short-term agenda focuses on practical projects like spoken medical records and optimized diagnostics for conditions such as stroke and pneumonia. These applications are yielding tangible benefits, including reduced errors, faster reporting times, and increased efficiency. As the market continues to evolve, future trends point to expanded use of digital twins and autonomous diagnostics, all while navigating the complex regulatory landscape to ensure safe and ethical adoption.
